Introduction
Epilepsy and migraine are co-morbid neurologic disorders that may share some similar underlying pathogenic mechanisms. Individuals with epilepsy are over two times more likely to have migraine compared to people without epilepsy and people with migraine are over two times more likely to have epilepsy compared to people without migraine [1] . Young adults with migraine have a 1.85 adjusted hazard ratio of subsequently developing epilepsy, compared to their peers without migraine [2] . Genetic and environmental factors are likely the cause of such comorbidity [3] . Migraine may precipitate epileptic seizures, epileptic seizures may induce post-ictal migraine, and rarely, a migraine-like headache is the most prominent manifestation of an epileptic seizure [4] .
While there have been several investigations into the relationship between migraine and epilepsy, a potential link between psychogenic non-epileptic seizures (PNES) and migraine has not been extensively evaluated. However, a recent study found that the presence of migraine increases the likelihood of a patient with seizures having PNES as opposed to epilepsy alone [5] . Based upon our clinical experience managing patients who have PNES, we hypothesized that migraine is common in these patients and that patients with PNES have migraine that is more severe (i.e. more frequent attacks, longer attack duration, greater migraine-related disability) and more treatment refractory compared to patients who have epilepsy and migraine. The objective of this study was to Purpose: Clinical observations suggest that psychogenic non-epileptic seizure (PNES) patients often have severe migraine, more severe than epilepsy patients. Investigations into migraine characteristics in patients with PNES are lacking. In this study we tested the hypothesis that, compared to epilepsy patients, PNES patients have more severe migraine, with more frequent and longer duration attacks that cause greater disability. Method: In this observational study, 633 patients with video-EEG proven epilepsy or PNES were identified from the Mayo Clinic Epilepsy Monitoring Unit database. Contacted patients were screened for migraine via a validated questionnaire, and when present, data regarding migraine characteristics were collected. Two-sample t-tests, chi square analyses, and Mann-Whitney U tests were used to compare migraine characteristics in PNES patients to those of epilepsy patients. Results: Data from 43 PNES patients with migraine and 29 epilepsy patients with migraine were available. Compared to epilepsy patients, PNES patients reported having more frequent headaches (mean 15.1 AE 9.8 vs. 8.1 AE 6.6 headache days/month, p < .001), more frequent migraine attacks (mean 6.5 AE 6.3 vs. 3.8. AE 4.1 migraines/month, p = .028), longer duration migraines (mean 39.5 AE 28.3 vs. 27.3 AE 20.1 h, p = .035), and more frequently had non-visual migraine auras (78.6% vs. 46.7% of patients with migraine auras, p = .033). Migraine-related disability scores were not different between PNES and epilepsy patients (median 39, interquartile range 89 vs. 25, interquartile range 60.6, p = .15). Conclusion: Compared to epilepsy patients with migraine, PNES patients with migraine report having a more severe form of migraine with more frequent and longer duration attacks that are more commonly associated with non-visual migraine auras.
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compare migraine characteristics in patients who have migraine and video-EEG diagnosed PNES to migraine characteristics in patients who have migraine and video-EEG diagnosed epilepsy. Confirming a link between PNES and migraine and determining the severity of migraine in patients with PNES could establish a need for screening PNES patients for the presence of migraine.
Methods
This study was approved by the Mayo Clinic Institutional Review Board (IRB). Since participation in this study was considered to pose minimal risks to subjects, verbal consent only (as opposed to written consent) was considered sufficient for collection of data over the telephone. However, collected data could only be used for this study if subjects signed and returned HIPAA authorization forms.
Patients were identified from an existing clinical database of patients who had been evaluated in the Mayo Clinic Epilepsy Monitoring Unit (EMU) between 2008 and 2014. The database was used to identify patients who were at least 18 years of age and who received an EMU discharge diagnosis of PNES or epilepsy. Patients were excluded from this study if they had an uncertain diagnosis at discharge or if they were diagnosed with both PNES and epilepsy.
We attempted to make telephone contact with all patients who met these inclusion and exclusion criteria. Since our goal was to contact and enroll all eligible patients, no power analysis was performed for determination of sample size. After verbal consent was obtained, subjects were screened for the presence of migraine using ID Migraine, a validated 3-item questionnaire that has a sensitivity of .81 (95% CI, .77-.85), a specificity of .75 (95% CI, .64-.84), and positive predictive value of .93 (95% CI, 89.9-95.8) for the diagnosis of migraine [6] . Subjects who screened in for migraine (gave an affirmative response on 2 of 3 questions) were then asked additional questions about their migraine and seizures through the use of standardized questionnaires and a standardized interview. These additional data included patient demographics (i.e. age and sex), migraine characteristics (i.e. headache frequency, headache duration, headache severity, presence and symptoms of migraine aura), migraine-related disability (via the Migraine Disability Assessment Scale [MIDAS]), and timing of migraines in relation to their non-epileptic or epileptic seizures (i.e. no temporal relationship, migraines start before seizures, seizures start before migraines) [7] . Subjects were also asked about their current and past use of migraine treatments. Subjects who had used migraine therapies selected their current and past therapies from a comprehensive list created by the Mayo Clinic Headache Center that was read to them.
Data were analyzed within SPSS (version 22.0, Armonk, NY; IBM Corp.). Descriptive statistics were used to report data and twosample t-tests, chi-squared tests and Mann-Whitney U tests were used for comparing PNES and epilepsy subjects. Uncorrected pvalues <.05 were considered significant. (Table 1) 
Results

Subjects
The EMU database contained 633 patients (Fig. 1 ). Of these 633 patients, 205 patients were consented for participation. This population included 88 patients with PNES and 117 with epilepsy. Fifty-three of the 88 patients with PNES (60.2%) had migraine as determined by their ID-Migraine answers and additional clinical information collected during the subsequent interview. Forty-five of the 117 epilepsy patients (38.5%) had migraine. Twenty-two patients were excluded due to a mixed diagnosis of PNES and epilepsy. Ten PNES patients and 16 epilepsy patients did not return their HIPAA forms and thus their data is not included in further analyses. Therefore, data from 72 subjects (43 with PNES and 29 with epilepsy) were available for this study. The flow diagram in Fig. 1 illustrates enrollment.
Twelve subjects were male and 60 were female, with no differences in sex distribution between PNES and epilepsy groups (p = .77). Subject ages ranged between 20 years and 82 years in the PNES group and between 21 years and 78 years in the epilepsy group. On average, PNES subjects were slightly older than epilepsy subjects (47.0 years AE 13.2 years vs. 40.2 years AE 13.4 years, p = .039).
Headache and migraine frequency, pain intensity and duration
PNES patients reported having more frequent headaches than patients with epilepsy (15.1 AE 9.8 headache days per month vs. 8.1 AE 6.6 headache days per month, p < .001). PNES patients also reported having more frequent migraine attacks than patients with epilepsy (6.5 AE 6.3 migraine attacks per month vs. 3.8 AE 4.1 migraine attacks per month, p = .028). There were no differences in average headache intensity between the PNES and epilepsy groups [6.6 AE 2.1 on a scale from 0 (no pain) to 10 (most severe pain) vs. 6.8 AE 1.8, p = .74]. Patients with PNES reported longer duration migraines (when untreated) compared to patients with epilepsy (39.5 AE 28.3 h vs. 27.3 AE 20.1 h, p = .035). 
Migraine aura status and characteristics
Migraine treatments
At the time of the interview, 17 of 43 (39.5%) PNES patients considered themselves to be taking a migraine prophylactic medication compared to 5 of 29 (17.2%) epilepsy patients who considered themselves to be taking a migraine prophylactic medication (p = .58). Twenty four of forty three (55.8%) PNES patients and 11 of 29 (37.9%) epilepsy patients had been prescribed a migraine abortive medication (p = .58). The total number of abortive medications (prescription + over-the-counter) ever used by PNES patients averaged 2.7 (AE1.6), compared to 3.5 (AE4) for epilepsy patients (p = .25). This included .86 (AE.95) prescription abortive medications in the PNES group and 1.6 (AE3.6) prescription abortive medications in the epilepsy group (p = .29). The total number of prophylactic therapies (prescription + non-prescription) ever tried by PNES patients averaged 1.9 (AE1.7) compared to 1.8 (AE2.7) for epilepsy patients (p = .83). The total number of prescription prophylactic medications ever tried averaged .88 (AE1.14) for PNES patients and .72 (AE1.6) for patients with epilepsy (p = .64). Twentythree of 43 (53.5%) PNES patients and 22 of 29 (75.9%) epilepsy patients felt that their migraines were adequately treated (p = .054). Nineteen of 43 (44.2%) PNES patients had never been prescribed a medication to abort migraines and 19 of 43 (44.2%) PNES patients considered themselves to have never been prescribed a migraine prophylactic medication.
Migraine-related disability
Migraine Disability Assessment (MIDAS) scores were consistent with severe migraine-related disability in both the PNES (median 39, interquartile range 89) and epilepsy groups (median 25, interquartile range 60.6). There were no significant differences in MIDAS scores between the two subject cohorts (p = .15). The proportion of patients with severe migraine-related disability did not significantly differ between subject groups, with 30 of 43 PNES patients (69.8%) having severe disability and 16 of 29 epilepsy patients (55%) having severe disability (p = .22).
Temporal relationship between migraine and seizures
Seventeen of forty three (39.5%) PNES patients and 10 of 29 (34.5%) epilepsy patients reported the presence of a temporal relationship between their migraines and their seizures (p = .66). Thirteen of 17 (76.5%) PNES patients and 6 of 10 (60%) epilepsy patients who had a temporal relationship between their migraines and seizures reported that they got migraines before their seizures (p = .82). Nine of 17 (52.9%) PNES patients and 6 of 10 (60%) epilepsy patients who had a temporal relationship between their migraines and seizures reported that they got migraines following their seizures (p = .72).
Discussion
The main purpose of this study was to assess migraine symptoms in patients with PNES and in patients with epilepsy to determine if migraine symptoms differ between these two patient groups. The main finding was that, compared to patients with epilepsy and migraine, patients with PNES reported having more frequent and longer duration migraines and they are more likely to have non-visual migraine aura symptoms. Since patients with PNES report having a particularly severe form of migraine and since only about one-half of PNES patients felt that their migraines were currently being adequately treated, clinicians should consider screening their PNES patients for migraine, and when present, treating them appropriately.
Few previously published studies have investigated the link between PNES and migraine. One study of 1000 migraine patients found that 16.5% of the migraine subjects had PNES as diagnosed via clinical symptoms and inter-ictal EEGs [8] . In another study, 61% of PNES subjects were diagnosed with headaches, although the specific headache types were not specified [9] . A recent study found that the presence of migraine increases the likelihood of a patient with seizures having PNES as opposed to epilepsy alone [5] . Our study adds to the existing literature by detailing specific migraine characteristics in patients with PNES.
The explanation for the link between PNES and migraine is unknown. We hypothesize that there could be a pathophysiologic link, in that the brain hypersensitivity and hypervigilance associated with migraine might also predispose a person to PNES. Although data regarding sensory hypersensitivity in patients with PNES are lacking, experts have suggested that PNES patients have low tolerance to sensory arousal, perhaps leading to sensory stimuli such as lights and noise triggering PNES attacks [10] . Similar sensory stimuli are commonly reported as migraine triggers. The link between migraine and PNES could be attributable to shared risk factors for development of both migraine and PNES including childhood sexual abuse and female sex [5, 11, 12] . PNES and migraine also share comorbid disorders including epilepsy, anxiety, depression, and extracephalic chronic pain including fibromyalgia and neuropathic pain [5, [13] [14] [15] [16] . In fact, a retrospective study suggested that the presence of fibromyalgia or ''chronic pain'' predicts a diagnosis of PNES in patients with refractory seizures [17] . Although we hypothesize that there is a pathophysiologic link between PNES and migraine, the results from this study cannot rule out the possibility that the somatization associated with PNES leads patients with PNES to report headaches and associated symptoms that resemble migraine, even in their absence [18] . Future studies that obtain measures of somatization will be informative for testing this possibility.
In this study, patients with PNES reported having more frequent and longer duration migraines. However, we are unable to differentiate whether PNES patients actually have more severe migraine or if they are hyperaware of their migraine symptoms and thus ''over-report'' the severity. A high level of somatization has previously been found in patients with PNES, and if present in our cohort of patients, could have impacted their self-report of migraine symptoms.
[18] Although we did not measure pain catastrophizing in this study, doing so will be a useful addition to future studies. Ascertainment of symptoms for this study was performed in a similar manner as is typically done in clinical practice. Since there are not objective methods of clinically determining the presence and severity of migraine symptoms, it is standard to accept that patientreported symptoms are in fact present. Furthermore, assessing a person's perception of their migraine symptoms is important, as it is this perception that likely mediates the extent of suffering that results. However, serving as evidence against the possibility that patients with PNES ''over-reported'' their migraine symptoms, the extent of migraine-related disability according to MIDAS scores was not different between patients with PNES and those with epilepsy. If the greater migraine burden that was reported by patients with PNES in this study was primarily due to over-interpretation of symptoms, we would expect that they would have also reported more days of migraine-related disability.
Major strengths of this study include that all patients were diagnosed with video EEG monitoring and a validated method was used for assigning a migraine diagnosis. Challenges encountered during the conduction of this research included: (1) we were not able to contact a large number of the patients who were included in the Mayo EMU database despite numerous attempts (as summarized in Fig. 1 ). Because a small percentage of the total patients in the EMU database were ultimately included in this study and because patients with migraine might have been more likely to participate, we are not able to estimate migraine prevalence in our population. (2) Migraine characteristics and migraine treatments were collected according to patient recall of information and the accuracy of the data could not be confirmed. Thus, recall bias is a likely limitation. This limitation should apply equally to the subjects with PNES and those with epilepsy. (3) Data regarding the use of migraine prophylactic medications were collected by asking subjects if they considered themselves to be taking such a medication. The question was purposefully worded this way in order to assess whether patients had been prescribed medication specifically for migraine prevention. However, it is possible that some patients were prescribed anti-seizure medications for treatment of their seizures and migraines, but were not made aware of the potential migraine preventive effects. (4) Subject compliance with migraine medications could not be measured in this study. Lack of compliance with treatment could affect migraine patterns. Table 1 Demographics and migraine characteristics in participants with PNES vs. Epilepsy. Pain intensity was measured on a scale from 0 (no pain) to 10 (most severe pain). ''Migraine attack duration'' corresponds to the duration (in hours) of an untreated migraine attack. ''Migraine auras'' is the percentage of patients who have migraine auras with at least some of their migraine attacks. ''Non-visual aura symptoms'' is the percentage of patients who have sensory, motor, or language aura symptoms with or without visual aura symptoms. ''Migraines adequately treated'' is the percentage of patients who reported that they felt their migraines were adequately treated. Migraine disability was assessed using the Migraine Disability Assessment (MIDAS) questionnaire. MIDAS scores of 21 or higher are indicative of severe migraine-related disability. SD = standard deviation. IQR = interquartile range. *p < .05.
PNES (n = 43)
Epilepsy (n = 29) 
Conclusions
This study found that compared to people with epilepsy and migraine, people with PNES and migraine report having a more severe form of migraine with more frequent and longer duration attacks. People with PNES were more likely than those with epilepsy to report having non-visual migraine aura symptoms. These findings justify the need for clinicians to assess PNES patients for the presence of migraine and when present, to treat them appropriately for migraine. We speculate that treatments for PNES could also help migraine and conversely, treatments for migraine could lead to improvements in PNES. Psychological treatments might play a particularly important role for patients with PNES and migraine. For example, cognitive behavioral therapy has been shown to provide benefits for patients with PNES as well as for those with migraine [19, 20] .
